

Supplemental Table 1: Backbone component drugs at baseline for participants in analytic sample (N=16,505)

| <b>Backbone Regimen</b> | <b>Drug 1</b>            | <b>Drug 2</b>      | <b>Percentage</b> |
|-------------------------|--------------------------|--------------------|-------------------|
| 1                       | Emtricitabine/Lamivudine | Tenofovir          | 69                |
| 2                       | Emtricitabine/Lamivudine | Abacavir           | 10                |
| 3                       | Emtricitabine/Lamivudine | Tenofovir/Abacavir | 4                 |
| 4                       | Emtricitabine/Lamivudine | Zidovudine         | 4                 |
| 5                       | Other <sup>a</sup>       |                    | 13                |

<sup>a</sup>Other backbone combinations include complex backbone combinations, NRTI-sparing regimens and salvage therapies.